







































Key words: pT1直腸癌（pT1 colorectal cancer），内視鏡的摘除後（after endoscopic resection），
 根治切除（radical resection）





















Podoplanin （D 2 -40）染色ではリンパ管浸潤は認めな






























































































Surveillance schedule after endoscopic 
resection
1 Masaki 8 ） 1999 5.6%（1/18） NA
0%
（0/1） NA NA NA














Only total CS 2 to 10 times （4.6 times on 
average）, not determined follow-up interval.









5 Ikematsu12） 2013 3.5%（8/226） NA
37.5%
（3/8） NA 55.2
PE, TM, CXR and CT every 6 months for the
first 3 years and thereafter every 12
months. Total CS every year. 









PE, TM, CXR and CT every 6 months for the
first 3 years, and thereafter every 12
months. Total CS every year.






（5-63） CT and TM every year, CS every 3-6 months.



















PE, TM, CXR and CT every 6 months for the
first 2 years, and thereafter every year
until 5 years. CS within the first year.














PE, TM, CXR and CT every 6 months for the
first 3 years, and thereafter every 12 months.







CS with or without biopsy, not determined
follow-up interval.











（4/4） NA 41.5 PE, TM, CT and total CS every year for 5 years.








（2-130） CS at 1 year, and then after 3 and 5 years.





TM, AXR and CT every 6 months for the
first 3 years and thereafter every 12
months. Total CS every year. 







TM every 3 months, CT every 6 months, CS
every year.







TM every 3 to 6 months, CT every 6 to 12

















で，術後 9日目に退院となった．2016年 1 月から術後
補助化学療法としてカペシタビン＋オキサリプラチン























の簇出（budding）BD 2 / 3 のいずれかを示す症例は，追





　1991年 1 月～2020年 5 月の期間において医学中央雑誌
で「リスク」，「再発」，「大腸癌」，「内視鏡的摘除」，「追
加切除」をキーワードとして検索した結果と1991年 1 月
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Abstract
A CASE OF LOCAL RECURRENCE IN THE PARARECTAL LYMPH NODES  
2 YEARS AFTER ENDOSCOPIC RESECTION OF PT1 RECTAL CANCER
Akira Takenouchi 1 ）, Mayumi Ozawa 1 ）, Atsushi Ishibe 1 ）, Yusuke Suwa 2 ）, 
Kazuya Nakagawa 1 ）, Jun Watanabe 2 ）, Takashi Hibiya 3 ）, Itaru Endo 1 ）
1 ）Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine 
2 ）Department of Surgery, Yokohama City University Medical Center, Gastroenterological Center 
3 ）Department of Pathology, Yokohama City University Graduate School of Medicine
　A 66-year-old male underwent colonoscopy, which identified an 0-Is polyp in the rectum. Endoscopic resection 
was then performed, and the histopathological examination showed SM massive, unknown vertical margin, and 
venous invasion. He was thus referred to our department for the purpose of additional resection. However, follow-up 
every 6 months was performed because of his wish to avoid additional resection. He underwent contrast-enhanced 
CT 2 years after the start of follow-up, and a swollen pararectal lymph node was found. Based on this examination, 
he was diagnosed with recurrent lymph node metastasis and underwent laparoscopic ultra-low anterior resection and 
diverting ileostomy. Histopathological examination showed well to moderately differentiated tubular adenocarcinoma 
in the mesorectum and metastasis in a pararectal lymph node. After 8 courses of XELOX therapy as postoperative 
adjuvant chemotherapy, he underwent stoma closure. He is alive without recurrence 4 years after surgery. Patients 
should be informed of the expected course of pT1 colorectal cancer along with factors that should be considered for 
additional resection, and they should be followed carefully.
